This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
Data sharing requests should be sent to Matthieu Duchmann (matthieu.duchmann@aphp.fr).
References
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:1–14.
Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023;37:1530–9.
Baer C, Huber S, Hutter S, Meggendorfer M, Nadarajah N, Walter W, et al. Risk prediction in MDS: independent validation of the IPSS-M-ready for routine? Leukemia. 2023;37:938–41.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol J Am Soc Clin Oncol. 2023;41:2827–42.
Huber S, Haferlach T, Müller H, Meggendorfer M, Hutter S, Hoermann G, et al. MDS subclassification—do we still have to count blasts? Leukemia. 2023;37:942–5.
Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134:1441–4.
Duployez N, Largeaud L, Duchmann M, Kim R, Rieunier J, Lambert J et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. In Press. https://doi.org/10.1182/blood.2021015328. 2022.
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141:534–49.
Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, et al. A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. 2016;101:918 LP–925.
Adès L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM’s ‘pick a winner’ trial, with the impact of somatic mutations. Br J Haematol. 2022;198:535–44.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. https://doi.org/10.1038/s41375-023-01999-6. 2023.
Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, et al. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023;7:3624–36.
Tiong IS, Stevenson WS, Wall M, Yap YZ, Seymour JF, Kenealy M et al. Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide. eJHaem. https://doi.org/10.1002/jha2.767. 2023.
Acknowledgements
We thank all investigators from the Groupe Français des Myélodysplasies (GFM). This study was supported by the GFM. MD was supported by the Bettencourt Schueller Foundation (CCA-INSERM-Bettencourt).
Author information
Authors and Affiliations
Contributions
MS, ND and MD designed the study. LF, CC, AG, PP, ST, OBR, SP, TC, FC, PF, SC, LA managed patients and clinical data. CP, EC and ND performed biological analyses. MD performed statistical analyses. MS, LA, ND and MD wrote the manuscript. All authors reviewed and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Sébert, M., Freiman, L., Chaffaut, C. et al. Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38, 918–922 (2024). https://doi.org/10.1038/s41375-024-02180-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-024-02180-3